A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Summary

The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.

Timeline

Start

2020-12-24

Primary completion

2021-08-27

Completion

2023-03-07

Outcome

Outcome not reported

Stopped (Business): “Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators.”

Drugs

Indications